Study of porcine and human isophane (NPH) insulins in normal subjects. 1984

D R Owens, and I R Jones, and A J Birtwell, and C T Burge, and S Luzio, and C J Davies, and P Heyburn, and L G Heding

The plasma glucose, C-peptide and insulin responses to subcutaneously administered highly purified porcine, 'semi-synthetic' and 'biosynthetic' human isophane (NPH) insulin and diluting medium as control in normal male subjects were evaluated. Porcine and semi-synthetic human NPH insulins were administered at two dose levels of 0.15 and 0.30 U/kg body weight and biosynthetic human NPH at 0.15 U/kg body weight only. At the low dose level the three insulin preparations resulted in a similar maximal hypoglycaemic effect within 3-5 h after administration. However, over the remainder of the 11 h post-injection period, the plasma glucose level was lower after semi-synthetic human insulin. In contrast, at the 0.30 U/kg dose level, there was no difference in the early or late hypoglycaemic response between porcine and semi-synthetic human NPH insulins of equivalent pharmaceutical formulation. The clinical relevance of these findings needs further evaluation. The data suggest that for the 'intermediate-acting' NPH insulin preparations, both the species of insulin, nature and quantity of the retarding protein and their subsequent interaction may determine their time-action characteristics.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007336 Insulin, Isophane An intermediate-acting INSULIN preparation with onset time of 2 hours and duration of 24 hours. It is produced by crystallizing ZINC-insulin-PROTAMINES at neutral pH 7. Thus it is called neutral protamine Hagedorn for inventor Hans Christian Hagedorn. Insulin, NPH,Insulin, Protamine Zinc,Isophane Insulin, Regular,NPH Insulin,Neutral Protamine Hagedorn Insulin,Protamine Hagedorn Insulin,Hagedorn Insulin, Protamine,Isophane Insulin,Protamine Zinc Insulin,Regular Isophane Insulin,Zinc Insulin, Protamine
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

D R Owens, and I R Jones, and A J Birtwell, and C T Burge, and S Luzio, and C J Davies, and P Heyburn, and L G Heding
January 1984, Acta medica Scandinavica,
D R Owens, and I R Jones, and A J Birtwell, and C T Burge, and S Luzio, and C J Davies, and P Heyburn, and L G Heding
January 1987, European journal of clinical pharmacology,
D R Owens, and I R Jones, and A J Birtwell, and C T Burge, and S Luzio, and C J Davies, and P Heyburn, and L G Heding
January 1987, Domestic animal endocrinology,
D R Owens, and I R Jones, and A J Birtwell, and C T Burge, and S Luzio, and C J Davies, and P Heyburn, and L G Heding
January 1981, Diabetes care,
D R Owens, and I R Jones, and A J Birtwell, and C T Burge, and S Luzio, and C J Davies, and P Heyburn, and L G Heding
January 1998, Diabetologia,
D R Owens, and I R Jones, and A J Birtwell, and C T Burge, and S Luzio, and C J Davies, and P Heyburn, and L G Heding
January 1989, Diabetic medicine : a journal of the British Diabetic Association,
D R Owens, and I R Jones, and A J Birtwell, and C T Burge, and S Luzio, and C J Davies, and P Heyburn, and L G Heding
July 1982, British medical journal (Clinical research ed.),
D R Owens, and I R Jones, and A J Birtwell, and C T Burge, and S Luzio, and C J Davies, and P Heyburn, and L G Heding
May 1993, Diabetes research and clinical practice,
D R Owens, and I R Jones, and A J Birtwell, and C T Burge, and S Luzio, and C J Davies, and P Heyburn, and L G Heding
February 1984, Acta endocrinologica,
D R Owens, and I R Jones, and A J Birtwell, and C T Burge, and S Luzio, and C J Davies, and P Heyburn, and L G Heding
January 1984, Acta diabetologica latina,
Copied contents to your clipboard!